Novogen Limited (NASDAQ:KZIA) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Novogen Limited (NASDAQ:KZIA) have been given a consensus recommendation of “Moderate Buy” by the six brokerages that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating and five have given a buy rating to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $25.80.

KZIA has been the subject of a number of analyst reports. BTIG Research reaffirmed a “buy” rating and issued a $34.00 price target on shares of Novogen in a report on Wednesday, July 15th. Lake Street Capital started coverage on Novogen in a report on Thursday, June 11th. They issued a “buy” rating and a $32.00 price objective on the stock. Laidlaw started coverage on Novogen in a research report on Wednesday, April 15th. They issued a “buy” rating and a $25.00 price objective for the company. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Novogen in a research note on Friday, July 17th.

Novogen Price Performance

KZIA stock opened at $12.82 on Friday. The company’s 50-day simple moving average is $13.11 and its 200-day simple moving average is $10.23. Novogen has a 52-week low of $4.86 and a 52-week high of $17.40.

About Novogen

Novogen (NASDAQ:KZIA) is a clinical-stage biotechnology company focused on the discovery and development of novel small-molecule therapeutics for the treatment of cancer. The company’s pipeline includes GDC-0084, a brain-penetrant phosphoinositide 3-kinase (PI3K) inhibitor in Phase II development for glioblastoma, as well as Cantrixil, an orally bioavailable small molecule designed to target treatment-resistant ovarian cancer stem cells. Novogen’s research efforts leverage structure-based drug design to optimize selectivity and pharmacokinetic profiles, seeking to address high-unmet medical needs in oncology.

Founded in Australia and now headquartered in New York City, Novogen maintains research facilities in Perth and collaborates with academic institutions and contract research organizations worldwide.